AtheroGenics, Inc.{AGIX}-nasdaq Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Clarksterh who wrote (276)	6/27/2007 11:18:40 PM
From: mlrb2113	Read Replies (1) of 332

ANDES: Mr. Clark: Dosages will be from 75 mg. to 300 mg. I would think they wouldn't go as low as 75 unless it has a chance of efficacy. Also, I'd think 75 would be very unlikely to show any toxicity. Therefor, I'd think they should get enough data to be able to show doseage vs. tox and doseage vs. efficacy, (or tox vs. efficacy). This would depend on whether LFTs are likely to vary with dose, or would they likely just go up suddenly in some patients with little correlation to doseage? Anyway, what do you think about it?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next